10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Henry G. Bone(University of Michigan), Rachel B. Wagman(Amgen (United States)), Maria Luisa Brandi(University of Florence), Jacques P. Brown(Quebec Research and Development Centre), Roland Chapurlat(Université Claude Bernard Lyon 1), Steven R. Cummings, E. J. Czerwiński(Krakow Cardiovascular Research Institute), Astrid Fahrleitner‐Pammer(Medical University of Graz), David L. Kendler(University of British Columbia), Kurt Lippuner(University Hospital of Bern), Jean‐Yves Reginster(University of Liège), Christian Roux(Délégation Paris 5), Jorge Malouf(Hospital de Sant Pau), Michelle N. Bradley(Amgen (United States)), Nadia Daizadeh(Amgen (United States)), Andrea Wang(Amgen (United States)), Paula Dakin(Amgen (United States)), Nicola Pannacciulli(Amgen (United States)), David W. Dempster(Helen Hayes Hospital), Socrates E. Papapoulos(Leiden University Medical Center)
The Lancet Diabetes & Endocrinology
May 22, 2017
Cited by 954Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis